Market-Moving News for October 24th
Portfolio Pulse from ryanfaloona@benzinga.com
Raytheon Technologies reported better-than-expected Q3 results, updated guidance, and announced a $10 billion accelerated share-repurchase program. InMed Pharmaceuticals revealed unique pharmacological effects of INM-901 in Alzheimer's disease in preclinical studies. LianBio entered into an agreement with Bristol Myers Squibb for Mavacamten in China and other Asian markets.
October 24, 2023 | 12:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
InMed Pharmaceuticals revealed unique pharmacological effects of INM-901 in Alzheimer's disease in preclinical studies.
The positive preclinical results of INM-901 for Alzheimer's disease could increase investor interest in InMed Pharmaceuticals. This could potentially lead to a rise in the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
LianBio entered into an agreement with Bristol Myers Squibb for Mavacamten in China and other Asian markets.
The partnership with Bristol Myers Squibb for Mavacamten in China and other Asian markets could open new revenue streams for LianBio. This could potentially lead to a rise in the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Raytheon Technologies reported better-than-expected Q3 results and announced a $10 billion accelerated share-repurchase program.
The better-than-expected Q3 results and the announcement of a $10 billion accelerated share-repurchase program are positive news for Raytheon Technologies. This could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100